Leerink analyst David Risinger lowered the firm’s price target on Structure Therapeutics (GPCR) to $44 from $60 and keeps an Outperform rating on the shares. The firm cites change to its terminal growth rate to reflect longer-term competition. Leerink notes that Structure reiterated that it continues to anticipate topline Phase 2b 36-week data from oral small molecule GLP-1 aleniglipron ACCESS and ACCESS II studies by year-end 2025. The company is also expanding aleniglipron’s clinical development program to optimize competitive positioning and its future Phase 3 program.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target lowered to $87 from $89 at Citizens JMP
- Structure Therapeutics Reports Q2 2025 Financial Results
- Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
- Structure Therapeutics files automatic mixed securities shelf
- Structure Therapeutics initiated with a Buy at Clear Street